Welsh, Carson, Anderson & Stowe, a private equity firm focused exclusively on the healthcare and technology industries, agreed to invest $250m in Kiniciti, which will invest in non-therapeutic companies supporting cell and gene therapy innovation. "Partnering with Kiniciti to help realize the promise of cell and gene therapy represents a natural extension for WCAS's Healthcare franchise. We will pursue opportunities where operational improvements, organic growth initiatives and strategic acquisitions can unlock full potential, for both our investments and the patients these companies serve. In today's cell and gene therapy landscape, we believe that there are many exciting therapy innovators that possess the right science but need the supporting ecosystem essential to advancing their therapeutics at the pace they require and deserve. We look forward to working with the Kiniciti team to help address these critical pain points to help deliver CGT at scale and lower cost," Nick O'Leary, WCAS General Partner.